Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab alone or in combination with Cyclophosphamide or Methotrexate in RA
NCT02693210Phase 2Completed
- Sponsor
- Roche
- Start
- Feb 2001
- Primary completion
- Aug 2002
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
Phase 2, randomised, double-blind trial of rituximab in rheumatoid arthritis (RA) (4 arms), sponsored by Roche. Primary endpoint: American College of Rheumatology 50% Response at 24 weeks. Started Feb 2001; status: completed.
02
Drugs
rituximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02693210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02693210.